GENTIUM S.p.A. (NASDAQ:GENT) Financial and Strategic Analysis Review
Gentium S.p.A. (Gentium) is a biopharmaceutical company, engaged in the discovery, development, and manufacture of drugs derived form the natural sources. The drugs are being developed to treat various vascular diseases and for conditions related to cancer and cancer treatments. The company was founded in 1993 as Pharma Research S.r.L. It is headquartered in Villa Guardia, Italy.
The GENTIUM S.p.A. - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of GENTIUM S.p.A.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.
Scope
- Provides key company information for business intelligence needs.
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
- The report contains critical company information – business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial and strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Capitalize on competitor's weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Table Of Contents
Key Information 1
Key Ratios 1
Share Data 1
Performance Chart 1
Table Of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
Business Description 4
Major Products and Services 4
Overview 4
History 5
SWOT Analysis Overview 6
Overview 6
GENTIUM S.p.A. - Strengths 6
Focused Research and Development Activities 6
Focus on Emerging Therapeutic Segments 6
GENTIUM S.p.A. - Weaknesses 6
History of Operating Losses 6
GENTIUM S.p.A. - Opportunities 6
Biotech Focus 6
Defibrotide in Phase III 6
Licensing and Distribution Agreements 7
GENTIUM S.p.A. - Threats 7
Stiff Competition 7
Tightening of FDA’s Regulatory Oversight 7
Emergence of Generic Products 7
Key Competitors 8
Key Employees 8
Key Employee Biographies 8
Locations And Subsidiaries 9
Head Office 9
Financial Ratios 10
Capital Market Ratios 10
Annual Ratios 10
Interim Ratios 11
Ratio Charts 12
Appendix 13
Methodology 13
Ratio Definitions 13
About Global Markets Direct 16
Contact Us 16
Disclaimer 16
List of Tables
GENTIUM S.p.A., Key Facts 1
GENTIUM S.p.A., Key Ratios 1
GENTIUM S.p.A., Share Data 1
GENTIUM S.p.A., Key Facts 4
GENTIUM S.p.A., History 5
GENTIUM S.p.A., Key Employees 8
GENTIUM S.p.A., Key Employee Biographies 8
GENTIUM S.p.A., Ratios based on current share price 10
GENTIUM S.p.A., Annual Ratios 10
GENTIUM S.p.A., Interim Ratios 11
Currency Codes 13
Capital Market Ratios 13
Equity Ratios 14
Profitability Ratios 14
Cost Ratios 14
Liquidity Ratios 15
Leverage Ratios 15
Efficiency Ratios 15
List of Figures
GENTIUM S.p.A., Performance Chart (2004 - 2008) 1
GENTIUM S.p.A., Ratio Charts 12